New Protein Therapy Shows Promise for Treating Age-Related Macular Degeneration

Researchers find that boosting IRAK-M protein in retinal cells could protect against vision loss in older adults.

Age-related macular degeneration (AMD) affects 200 million people globally, projected to rise to 288 million by 2040.
The study demonstrates that increasing IRAK-M protein levels can significantly protect retinal cells from degeneration.
Current AMD treatments target single pathways; the new therapy addresses multiple pathways for a more effective solution.
The research was conducted by the University of Bristol, Cirrus Therapeutics, and the Global University Institute of Ophthalmology.
The findings suggest a potential new gene therapy for AMD, offering hope for millions suffering from this condition.